Gemoscan Completes R&D on Pet Food Intolerance Test

Gemoscan Completes R&D on Pet Food Intolerance Test

Leading Food Intolerance Management Provider Poised to Enter the Lucrative
Veterinary Market

TORONTO, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. (TSX-V:GES)
(MUN:1GE) ("Gemoscan" or the "Company"), a leading owner and marketer of food
sensitivity and dietary management solutions, announced today that it has
completed research, development and beta testing of a unique Pet Food
Intolerance Test ("PFIT").

While the market and prevalence of food intolerance and allergy in cats and
dogs is still being quantified, some research shows that up to 10% suffer from
intolerances. Further, adverse food reactions account for up to 6% of all
canine and feline dermatoses in general veterinary practice and as high as 20%
of all cases in animal dermatology practices. Common symptoms of food
intolerance in pets include: flaky skin, constant scratching, chewing or
biting areas of the skin, dry or rough skin, fur loss, hives, rashes, skin
irritations or hot spots, vomiting, diarrhea, nausea and lethargy. While
adverse food reactions are not known to be breed exclusive, their prevalence
does tend to vary from breed to breed. These symptoms, while not life
threatening, impact the quality of life for pets, as do the conditions
associated with food intolerance for humans.

Gemoscan's PFIT management program is based on the Company's patented blood
testing technology, portions of which are successfully used to manage food
intolerances in humans through its groundbreaking HEMOCODE™ and MenuWise™
retail programs.The PFIT test assess for 80 foods and additives, more than
any other similar program on the market.The test was developed in close
consultation with veterinary doctors, while the ingredients being analyzed
were determined after a careful review of approximately 100 different
commercially available dry and canned foods.

"We believe that targeting pet health and wellness is a natural extension for
Gemoscan. Applying our proven technology, systems and distribution
capabilities to this large and rapidly expanding market will be an important
growth driver for us going forward and will strengthen our leadership position
in the emerging food intolerance industry," said Brian Kalish, Gemoscan's
President and Chief Executive Officer.

ABOUT GEMOSCAN CANADA, INC.

Gemoscan is an industry leader in food intolerance management and maintains a
first-to-market position with Canada wide distribution through select retail
partners. Founded in 2003, using its proprietary patented technology, Gemoscan
develops, owns and markets comprehensive food sensitivity and dietary
management solutions for consumers, including the HEMOCODE™ Food Intolerance
System and the MenuWise^TM Food Intolerance Plan, personalized
naturopathically supervised nutritional programs that promote well-being.
Gemoscan is the first and only provider to commercialize a food intolerance
management solution directly to consumers in partnership with retailers, and
today offers the most comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under
the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock
Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All
statements, other than statements of historical fact that address activities,
events or developments that Gemoscan believes, expects or anticipates will or
may occur in the future. These forward-looking statements reflect the current
expectations or beliefs of Gemoscan based on information currently available
to Gemoscan. Forward-looking statements are subject to a number of significant
risks and uncertainties and other factors that may cause the actual results of
Gemoscan to differ materially from those discussed in the forward-looking
statements, and even if such actual results are realized or substantially
realized, there can be no assurance that they will have the expected
consequences to, or effects on Gemoscan. Any forward-looking statement speaks
only as of the date on which it is made and, except as may be required by
applicable securities laws, Gemoscan disclaims any intent or obligation to
update any forward- looking statement, whether as a result of new information,
future events or results or otherwise. Although Gemoscan believes that the
assumptions inherent in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of future performance and
accordingly undue reliance should not be put on such statements due to the
inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

CONTACT: Company:
        
         Brian Kalish
         Chief Executive Officer
         Gemoscan Canada, Inc.
         416.650.1200
         bkalish@hemocode.com
         www.gemoscan.com
        
         Media:
        
         Leonard Zehr
         Kilmer Lucas Inc.
         T: (416) 833-9317
         leonard@kilmerlucas.com
 
Press spacebar to pause and continue. Press esc to stop.